When it comes to oral semaglutide, the OASIS-1 trial showed that it led to a 15.1% reduction in body weight. But this was at ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

The state’s largest commercial health insurer will stop covering a popular class of prescription drugs for weight loss, ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035.

Injectable drugs require refrigeration when they are stored or transported, and the pill potentially opens up the market ...

Eli Lilly has announced a daily pill that lowers blood sugar levels and promotes weight loss in individuals suffering from ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

Eli Lilly shares are now positive for the year, up 10% since the start of January.